Filter posts

Riding the Bull Market: What’s in Store for Biotech Dealmakers in 2015?

In many ways, 2014 was a record year for biopharma dealmaking, with $355 billion in …

The Next Step: How Companies Build Successful Therapeutic Franchises from the Ground Up

Building a new franchise in a therapeutic from scratch poses a host of challenges, from …

How to Grow a Sustainable Biotech Company? Three Success Stories

Katrine Bosley, CEO of Editas Medicine kicked off the session by introducing panelists from three …

Outdated Payments Systems Aren’t Keeping Pace With Medical Innovation

We are experiencing an era of rapid medical progress thanks to the accelerated pace at …

Business Development and Building the Relationship After BIO

There is a great energy here at BIO, and you can feel it as you …

Pharma R&D Pipeline Value Jumps 18 Percent to $493 Billion

The pharmaceutical industry continues its impressive two-year growth with no signs of slowing down according …

Life Science Leader Asks: What Biopharma Trends Should Pharma Execs Be Paying Attention To?

In my last installment of this four-part series interviewing Peter Young, executive-in-residence with A.M. Pappas & …

Life Science Leader Asks: What Areas Are Often Overlooked by Academics Turned Biotech Entrepreneurs?

In my third installment of a four-part series interviewing Peter Young, executive-in-residence with A.M. Pappas …

State of the Industry for Emerging Therapeutic Companies

Emerging therapeutic companies are at their strongest point in a decade. In our new report …

Maximize Your Savings Potential During BIO International Convention

$161,000,000 That’s how much BIO saved life science companies in aggregate on their 2014 purchases …